Could common statins be a surprise weapon against brittle bones?

NCT ID NCT07717788

Completed Disease control Sponsor: Alkufa university\\collage of pharmacy Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks at whether adding a statin (atorvastatin or rosuvastatin) to standard osteoporosis treatment can improve bone density in postmenopausal women. Participants are women aged 55 and older with osteoporosis who also have high cholesterol. The trial compares standard therapy alone versus standard therapy plus one of the two statins, measuring changes in bone density and bone turnover markers over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atorvastatin and rosuvastatin, added to standard osteoporosis therapy (alendronate, calcium, vitamin D)
What this could lead to: If statins help build bone, this could point to a dual-purpose treatment for postmenopausal women with both high cholesterol and osteoporosis.
What could go wrong: This is a small, early-stage study with only 65 participants. Statins are not proven to treat osteoporosis, and any bone benefits may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS, POSTMENOPAUSAL STATIN THERAPY

Contacts and locations

Show contact details

Locations

AL-KUFA UNIVERSITY/College of Pharmacy

Najaf, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.